All In Biotech

NDA 020258 · Harrow Eye

Iopidine

Apraclonidine Hydrochloride · Ophthalmic

Priority review

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Jul 30, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

8

4 Phase 3, 2 recruiting

FAERS reports

111

87 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 2, 2024.

INDICATIONS AND USAGE Apraclonidine ophthalmic solution 0.5% is indicated for short-term adjunctive therapy, in patients on maximally tolerated medical therapy, who require additional IOP reduction. Patients on maximally tolerated medical therapy, who are treated with apraclonidine ophthalmic solution 0.5% to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the IOP rises significantly. The addition of apraclonidine ophthalmic solution 0.5% to patients already using two aqueous suppressing drugs (i.e., beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because apraclonidine ophthalmic solution 0.5% is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP. The IOP lowering efficacy of apraclonidine ophthalmic solution 0.5% diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than one month.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 30, 1993 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
  • IOPIDINE · APRACLONIDINE HYDROCHLORIDE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Apraclonidine" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective21
  • off label use7
  • somnolence7
  • eyelid ptosis6
  • vision blurred6
  • constipation5
  • dry mouth5
  • dyspnoea5
  • eye pain5
  • sinus bradycardia5
  • tenderness5
  • urinary retention5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20073
20088
20092
20111
20148
20153
20164
20177
201813
20197
202010
20217
20228
20238
202410
20254
20268

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Iopidine (Apraclonidine HCl)

2024 spending

$37K

Beneficiaries

31

48 claims

Per beneficiary

$1,205

$26.80 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$37,350

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 101 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.